Cargando…

Rapid HIV disease progression following superinfection in an HLA-B*27:05/B*57:01-positive transmission recipient

BACKGROUND: The factors determining differential HIV disease outcome among individuals expressing protective HLA alleles such as HLA-B*27:05 and HLA-B*57:01 remain unknown. We here analyse two HIV-infected subjects expressing both HLA-B*27:05 and HLA-B*57:01. One subject maintained low-to-undetectab...

Descripción completa

Detalles Bibliográficos
Autores principales: Brener, Jacqui, Gall, Astrid, Hurst, Jacob, Batorsky, Rebecca, Lavandier, Nora, Chen, Fabian, Edwards, Anne, Bolton, Chrissy, Dsouza, Reena, Allen, Todd, Pybus, Oliver G., Kellam, Paul, Matthews, Philippa C., Goulder, Philip J. R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5771019/
https://www.ncbi.nlm.nih.gov/pubmed/29338738
http://dx.doi.org/10.1186/s12977-018-0390-9
_version_ 1783293180640231424
author Brener, Jacqui
Gall, Astrid
Hurst, Jacob
Batorsky, Rebecca
Lavandier, Nora
Chen, Fabian
Edwards, Anne
Bolton, Chrissy
Dsouza, Reena
Allen, Todd
Pybus, Oliver G.
Kellam, Paul
Matthews, Philippa C.
Goulder, Philip J. R.
author_facet Brener, Jacqui
Gall, Astrid
Hurst, Jacob
Batorsky, Rebecca
Lavandier, Nora
Chen, Fabian
Edwards, Anne
Bolton, Chrissy
Dsouza, Reena
Allen, Todd
Pybus, Oliver G.
Kellam, Paul
Matthews, Philippa C.
Goulder, Philip J. R.
author_sort Brener, Jacqui
collection PubMed
description BACKGROUND: The factors determining differential HIV disease outcome among individuals expressing protective HLA alleles such as HLA-B*27:05 and HLA-B*57:01 remain unknown. We here analyse two HIV-infected subjects expressing both HLA-B*27:05 and HLA-B*57:01. One subject maintained low-to-undetectable viral loads for more than a decade of follow up. The other progressed to AIDS in < 3 years. RESULTS: The rapid progressor was the recipient within a known transmission pair, enabling virus sequences to be tracked from transmission. Progression was associated with a 12% Gag sequence change and 26% Nef sequence change at the amino acid level within 2 years. Although next generation sequencing from early timepoints indicated that multiple CD8+ cytotoxic T lymphocyte (CTL) escape mutants were being selected prior to superinfection, < 4% of the amino acid changes arising from superinfection could be ascribed to CTL escape. Analysis of an HLA-B*27:05/B*57:01 non-progressor, in contrast, demonstrated minimal virus sequence diversification (1.1% Gag amino acid sequence change over 10 years), and dominant HIV-specific CTL responses previously shown to be effective in control of viraemia were maintained. Clonal sequencing demonstrated that escape variants were generated within the non-progressor, but in many cases were not selected. In the rapid progressor, progression occurred despite substantial reductions in viral replicative capacity (VRC), and non-progression in the elite controller despite relatively high VRC. CONCLUSIONS: These data are consistent with previous studies demonstrating rapid progression in association with superinfection and that rapid disease progression can occur despite the relatively the low VRC that is typically observed in the setting of multiple CTL escape mutants. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12977-018-0390-9) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5771019
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-57710192018-01-25 Rapid HIV disease progression following superinfection in an HLA-B*27:05/B*57:01-positive transmission recipient Brener, Jacqui Gall, Astrid Hurst, Jacob Batorsky, Rebecca Lavandier, Nora Chen, Fabian Edwards, Anne Bolton, Chrissy Dsouza, Reena Allen, Todd Pybus, Oliver G. Kellam, Paul Matthews, Philippa C. Goulder, Philip J. R. Retrovirology Research BACKGROUND: The factors determining differential HIV disease outcome among individuals expressing protective HLA alleles such as HLA-B*27:05 and HLA-B*57:01 remain unknown. We here analyse two HIV-infected subjects expressing both HLA-B*27:05 and HLA-B*57:01. One subject maintained low-to-undetectable viral loads for more than a decade of follow up. The other progressed to AIDS in < 3 years. RESULTS: The rapid progressor was the recipient within a known transmission pair, enabling virus sequences to be tracked from transmission. Progression was associated with a 12% Gag sequence change and 26% Nef sequence change at the amino acid level within 2 years. Although next generation sequencing from early timepoints indicated that multiple CD8+ cytotoxic T lymphocyte (CTL) escape mutants were being selected prior to superinfection, < 4% of the amino acid changes arising from superinfection could be ascribed to CTL escape. Analysis of an HLA-B*27:05/B*57:01 non-progressor, in contrast, demonstrated minimal virus sequence diversification (1.1% Gag amino acid sequence change over 10 years), and dominant HIV-specific CTL responses previously shown to be effective in control of viraemia were maintained. Clonal sequencing demonstrated that escape variants were generated within the non-progressor, but in many cases were not selected. In the rapid progressor, progression occurred despite substantial reductions in viral replicative capacity (VRC), and non-progression in the elite controller despite relatively high VRC. CONCLUSIONS: These data are consistent with previous studies demonstrating rapid progression in association with superinfection and that rapid disease progression can occur despite the relatively the low VRC that is typically observed in the setting of multiple CTL escape mutants. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12977-018-0390-9) contains supplementary material, which is available to authorized users. BioMed Central 2018-01-16 /pmc/articles/PMC5771019/ /pubmed/29338738 http://dx.doi.org/10.1186/s12977-018-0390-9 Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Brener, Jacqui
Gall, Astrid
Hurst, Jacob
Batorsky, Rebecca
Lavandier, Nora
Chen, Fabian
Edwards, Anne
Bolton, Chrissy
Dsouza, Reena
Allen, Todd
Pybus, Oliver G.
Kellam, Paul
Matthews, Philippa C.
Goulder, Philip J. R.
Rapid HIV disease progression following superinfection in an HLA-B*27:05/B*57:01-positive transmission recipient
title Rapid HIV disease progression following superinfection in an HLA-B*27:05/B*57:01-positive transmission recipient
title_full Rapid HIV disease progression following superinfection in an HLA-B*27:05/B*57:01-positive transmission recipient
title_fullStr Rapid HIV disease progression following superinfection in an HLA-B*27:05/B*57:01-positive transmission recipient
title_full_unstemmed Rapid HIV disease progression following superinfection in an HLA-B*27:05/B*57:01-positive transmission recipient
title_short Rapid HIV disease progression following superinfection in an HLA-B*27:05/B*57:01-positive transmission recipient
title_sort rapid hiv disease progression following superinfection in an hla-b*27:05/b*57:01-positive transmission recipient
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5771019/
https://www.ncbi.nlm.nih.gov/pubmed/29338738
http://dx.doi.org/10.1186/s12977-018-0390-9
work_keys_str_mv AT brenerjacqui rapidhivdiseaseprogressionfollowingsuperinfectioninanhlab2705b5701positivetransmissionrecipient
AT gallastrid rapidhivdiseaseprogressionfollowingsuperinfectioninanhlab2705b5701positivetransmissionrecipient
AT hurstjacob rapidhivdiseaseprogressionfollowingsuperinfectioninanhlab2705b5701positivetransmissionrecipient
AT batorskyrebecca rapidhivdiseaseprogressionfollowingsuperinfectioninanhlab2705b5701positivetransmissionrecipient
AT lavandiernora rapidhivdiseaseprogressionfollowingsuperinfectioninanhlab2705b5701positivetransmissionrecipient
AT chenfabian rapidhivdiseaseprogressionfollowingsuperinfectioninanhlab2705b5701positivetransmissionrecipient
AT edwardsanne rapidhivdiseaseprogressionfollowingsuperinfectioninanhlab2705b5701positivetransmissionrecipient
AT boltonchrissy rapidhivdiseaseprogressionfollowingsuperinfectioninanhlab2705b5701positivetransmissionrecipient
AT dsouzareena rapidhivdiseaseprogressionfollowingsuperinfectioninanhlab2705b5701positivetransmissionrecipient
AT allentodd rapidhivdiseaseprogressionfollowingsuperinfectioninanhlab2705b5701positivetransmissionrecipient
AT pybusoliverg rapidhivdiseaseprogressionfollowingsuperinfectioninanhlab2705b5701positivetransmissionrecipient
AT kellampaul rapidhivdiseaseprogressionfollowingsuperinfectioninanhlab2705b5701positivetransmissionrecipient
AT matthewsphilippac rapidhivdiseaseprogressionfollowingsuperinfectioninanhlab2705b5701positivetransmissionrecipient
AT goulderphilipjr rapidhivdiseaseprogressionfollowingsuperinfectioninanhlab2705b5701positivetransmissionrecipient